Clinical Trial Update: A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating Tozuleristide as a fluorescent tumor marking agent for imaging oral cavity squamous cell carcinoma and high-grade oral cav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lip and Oral Cavity Cancer
• Oral Cavity Dysplasia
• Oral Cavity Squamous Cell Carcinoma

Drugs mentioned

• Tozuleristide (tozuleristide)

Snippet

Sponsor: University of Washington | Conditions: Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8 | Phase 1, Phase 2 | Status: TERMINATED